Category Archives: Insulin Delivery

Abbott’s Libre Duo Approved by FDA; AZ Initiates Pivotal Amylin Studies; New Lilly Medicare Obesity Ad; Lilly Initiates First Clazakizumab Study; Google Pixel Watch Non-Invasive Insulin Resistance; Revier Seed Financing for HFpEF and ASCVD; Haisco Partners with US-Based VC for Spinout

A series of cardiometabolic-related news items has been observed from Abbott, AstraZeneca, Lilly, Google, Revier Therapeutics, and Haisco Pharmaceutical. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Structure, Senseonics, Tandem, and Biocon Q2 ’26 Earnings

A series of cardiometabolic-related news items has been observed from Structure Therapeutics, Senseonics, Tandem Diabetes Care, and Biocon. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Ionis Q2 ’26 Earnings; FDA Revised Draft Guidance for Generic AOMs; Beta Bionics Q2 ’26 Earnings

Three cardiometabolic-related news items have been observed: Ionis hosted its Q2 ’26 earnings call (press release; slides); FDA published revised draft guidance for 17 peptides (view press release); and Beta Bionics hosted its Q2 ’26 earnings call (view press release; slides). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

AZ Q2 ’26 Earnings; Ex-Dexcom Executive Joins Luna Diabetes; Ascletis Preclinical Tri-Agonist Data; Ionis Pediatric Olezarsen Study; Lexicon Ph3 Sota Study; Veru Ph2b Enobosarm Study

A series of cardiometabolic-related news items has been observed from AstraZeneca, Luna Diabetes, Ascletis Pharma, Ionis Pharmaceuticals, Lexicon Pharmaceuticals, and Veru. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here